127 related articles for article (PubMed ID: 38701137)
1. PD-1/PD-L1 pathway: Current research in breast cancer.
Syamsu SA; Faruk M; Smaradania N; Sampepajung E; Pranoto AS; Irsandy F; Tammasse IFU
Breast Dis; 2024; 43(1):79-92. PubMed ID: 38701137
[TBL] [Abstract][Full Text] [Related]
2. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
4. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
6. A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism.
Zhu WY; Jin XY
Ann Palliat Med; 2021 Sep; 10(9):10075-10082. PubMed ID: 34628927
[TBL] [Abstract][Full Text] [Related]
7. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review.
Prihantono ; Rusli R; Christeven R; Faruk M
Ethiop J Health Sci; 2023 May; 33(3):515-522. PubMed ID: 37576162
[TBL] [Abstract][Full Text] [Related]
8. Hallmarks of Cancer: New Dimensions.
Hanahan D
Cancer Discov; 2022 Jan; 12(1):31-46. PubMed ID: 35022204
[TBL] [Abstract][Full Text] [Related]
9. Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery.
Kwon YW; Jo HS; Bae S; Seo Y; Song P; Song M; Yoon JH
Front Med (Lausanne); 2021; 8():747333. PubMed ID: 34631760
[TBL] [Abstract][Full Text] [Related]
10. Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers.
Keelan S; Flanagan M; Hill ADK
Front Oncol; 2021; 11():622621. PubMed ID: 34422626
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 pathway: current researches in cancer.
Han Y; Liu D; Li L
Am J Cancer Res; 2020; 10(3):727-742. PubMed ID: 32266087
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy.
Zhong X; Zhang H; Zhu Y; Liang Y; Yuan Z; Li J; Li J; Li X; Jia Y; He T; Zhu J; Sun Y; Jiang W; Zhang H; Wang C; Ke Z
Mol Cancer; 2020 Jan; 19(1):15. PubMed ID: 31980023
[TBL] [Abstract][Full Text] [Related]
13. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
